Intravenous tenecteplase in acute ischemic stroke: an updated review
- 915 Downloads
Tenecteplase in a genetically engineered variant of alteplase. Although the two have the same mechanism of action, tenecteplase has properties that makes it a seemingly more advantageous thrombolytic. Because of its rapid single-bolus administration, its use is favored over alteplase in the treatment of acute myocardial infarction. Over the past few years, several clinical studies have been conducted to assess the safety, feasibility, and efficacy of tenecteplase in ischemic stroke. In spite of the mixed results of these studies, experimentation with tenecteplase continues in from of clinical trials. In this article, the utility of tenecteplase in ischemic stroke will be discussed.
KeywordsStroke Cerebrovascular disease Tenecteplase Alteplase Tissue plasminogen activator Thrombolytics Thrombolysis Pharmacology
Conflicts of interest
Dr. Behrouz has received educational grant from Genentech Inc. The author declares that he has no conflict of interest.
- 16.ClinicalTrials.gov. TNK-tPA Evaluation for Minor Ischemic Stroke with Proven Occlusion (TEMPO-1). http://clinicaltrials.gov/ct2/show/NCT01654445?term=tenecteplase&rank=6
- 17.ClinicalTrials.gov. Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST). http://clinicaltrials.gov/ct2/show/NCT01472926?term=tenecteplase&rank=4